Adapting to Industry Rebound: The Next Phase of Clinical Trials

What does a recovering clinical research market actually look like in 2026?In this episode, Joel White, Owner of Market Cap Consulting, and Ryan Gifford, Vice President, Global Laboratory Services, Business Development & Client Management at CTI, join us to unpack the state of the industry—from the rebound in biotech funding to the growing importance of execution, site relationships, and smarter trial design.We explore how increasing complexity is shaping partnerships, how labs and decentralized models are evolving, and what it will take to keep trials on track. Looking ahead, the conversation offers a practical perspective on what the next 12–18 months could bring. 01:00 Guest backgrounds: Joel White (Market Cap Consulting) and Ryan Gifford (CTI) 02:45 Market recovery and funding trends05:15 Trial success: early collaboration and site relationships08:15 Funding challenges and execution impacts 10:30 Reducing site burden through lab operations and logistics 14:15 Decentralized trials and patient experience16:25 Regulatory shifts, AI, and growing data complexity19:30 Future outlook: partnerships and global trial expansion 23:30 Key takeaways and rapid-fire insights